

Ninth Global Summit PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

Save the Dates
September 15-17, 2025

Creating the Future of Patient Care

Faculty Members

Faina Shtern, MD, President & Founder, AdMeTech Foundation; Event Chair

David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York

Peter Albers, MD, Professor and Chairman, Department of Urology and Medical Director, Comprehensive Cancer Center, University Hospital, Heinrich-Heine-University, Düsseldorf; Professor of Urology and Division Head, Personalized Early Detection of Prostate Cancer, German Cancer Research Center, Heidelberg, Germany; and Chairman, Scientific Congress Office, European Association of Urology (TBC)

Paul Boutros, PhD, MBA Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA

Wayne Brisbane, MD, Assistant Professor of Urology, UCLA (TBC)

Irene Burger, MD, Head of Nuclear Medicine, Kantonsspital Baden, Baden Switzerland; Attending Nuclear Medicine, University Hospital Zurich, Switzerland

Sigrid Carlsson, MD, PhD, MPH, Assistant Attending Epidemiologist, Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden

Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University

Matthew Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF (TBC)

E David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal

Amita Dave, PhD, Attending Physicist and Deputy Service Chief for Predictive Informatics, Director of Quantitative Imaging, Memorial Sloan Kettering Cancer Center

David Einstein, MD, Assistant Professor, Harvard Medical School and Attending Physician, BIDMC Genitourinary Medical Oncology Program

Mark Emberton, PhD, Dean, Faculty of Medical Sciences, University College London; Professor of interventional oncology, Division of Surgery and Interventional Science, UCL; Honorary consultant urologist, UCLH

Stefano Fanti, MD, Professor, Department of Medical and Surgical Sciences, Head of Nuclear Medicine, University of Bologna, Italy

Steven Eric Finkelstein, MD, DABR, FACRO Director of the Center of Advanced Radiation Excellence (CARE); and Director, Radiation Oncology Research, Associated Medical Professionals, Syracuse, NY

Jurgen Futterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, Radboud UMC Nijmegen, The Netherlands; and Professor, Robotics and Mechanics Group, University of Twente, the Netherlands

Marc Garnick, MD, Director of Cancer Community Services, Network Development, BIDMC, Gorman Brothers Clinical Professor of Medicine at Harvard Medical School; and Special Advisor, Oncologic Drugs Advisory Committee of the FDA

Francesco Giganti, MD, PhD, Associate Professor of Radiology, Faculty of Medical Sciences, University College London, Honorary Consultant Radiologist, University College London Hospitals

Ilya Gipp, MD, PhD, Chief Medical Officer- Oncology, GE Healthcare

Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital, Professor of Radiology, Harvard Medical School

Raja B. Khauli, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign

Adam Kibel, MD, Elliott Carr, Cutler Professor of Surgery, Harvard Medical School; Chief of Urology, Brigham and Women's Hospital and Dana-Farber Cancer Institute (TBC)

Laurence Klotz, MD, FRCS, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center; and Chair, World Urologic Oncology Federation, University of Toronto, Sunnybrook Medical Center

Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University

Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology and Preventive Medicine, Northwestern Medicine - Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health (TBC)

Bruno Nahar, MD, Associate Professor of Urologic Oncology, Eric and Elizabeth Feder Endowed Chair in Urologic Oncology Research, Desai Sethi Urology Institute, University of Miami Miller School of Medicine

David Nanus, MD, Mark W. Pasantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital - Weill Cornell Medicine Healthcare System Cancer Program

Jane Nguyen, MD, PhD, Assistant Professor of Pathology at the Case Western Reserve University/Lerner College of Medicine; Director of Genitourinary Pathology, Staff Pathologist in the Diagnostics Institute, Department of Pathology and Laboratory Medicine at the Cleveland Clinic

Gladell P. Paner, MD, Professor of Pathology and Surgery (Urology), and Director of Genitourinary Pathology Service, University of Chicago

Sanoj Punnen, MD, MAS, Co-Chair of Genitourinary Site Disease Group, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research and Associate Professor, Department of Urology, University of Miami, Miller School of Medicine (TBC)

Monique Roobol, PhD, Professor of Decision Making in Urology and the Head of the Scientific Research Office, Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands (TBC)

Rakesh Shiradkar, PhD, Assistant Professor, BioHealth Informatics, Indiana University

Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine

Geoffrey Sonn, MD, Associate Professor of Urology and Radiology, Stanford University School of Medicine

Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel (TBC)

Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University of Tuebingen, Germany; Secretary General Adjunct - European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors

Clare M. C. Tempany-Afdhal, MB, BAO, BCh, Center of Cancer Research (TBC) Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women's Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization (TBC)

Baris Turkbey, MD, Senior Clinician, Molecular Imaging, Center for Cancer Research, National Cancer Institute, National Institutes of Health (TBC)

Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center (TBC)

Liang Wang, MD PhD, Professor, Attending Radiologist, Vice-Chair for the Research and Development, Director of Urogenital Imaging, Department of Radiology, Beijing Friendship Hospital Capital Medical University, China

Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine (TBC)

SILVER SPONSOR



EXHIBITOR



Ninth Global Summit PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

Save the Dates
September 15-17, 2025

Creating the Future of Patient Care

This Summit is convening the key international opinion leaders and generating a cross-disciplinary dialogue, which has become seminal in shaping the state of the art and new vision for precision management of prostate cancer.

We invite you to discuss the current and cutting-edge innovations and their role in improving patient management. You will support medical education and consensus development on the best emerging clinical practices and research priorities, and novel strategies for expedited acceptance of promising diagnostics and therapeutics.

SPONSORSHIP LEVELS

PLATINUM LEVEL (\$50,000)

- 1) Sponsored Symposium or Presentation(s) during the main program (up to 45 minutes), to be retained on the event website pages and featured in the newsletters of the AdMeTech and Grand Rounds in Urology (GRU), with a combined outreach to over 21,000 medical professionals at no additional cost (\$7,000 value)
- 2) Pre-Summit Virtual Workshop (1 hour) - Limited to four sponsors
- 3) Commercial video(s) (up to 10 minutes), shown during main program and retained on the event pages of the AdMeTech and GRU's websites
- 4) 12 complimentary registrations and 10 discounted (50%) registrations
- 5) 6 complimentary tickets to Virtual VIP Strategic Discussions for Speakers and Sponsors (by invitations only).
- 6) For additional benefits, see items 6-7 under Gold Level

GOLD LEVEL (\$25,000)

- 1) Sponsored Symposium or Presentation(s) during the main program (up to 22 minutes), to be retained on the event website pages and featured in the newsletters of the AdMeTech and GRU with a combined outreach to over 21,000 medical professionals at no additional cost (\$7,000 value)
- 2) Pre-Summit Virtual Workshop (30 minutes) - Limited to six sponsors
- 3) Commercial video(s) (up to 5 minutes), shown during main program and retained on the event pages of the AdMeTech and GRU's websites
- 4) 5 complimentary registrations and 5 discounted (50%) registrations
- 5) 4 complimentary tickets to Virtual VIP Strategic Discussions for Speakers and Sponsors (by invitations only).
- 6) Full-page digital ads and other company info (including links) for the event pages of the AdMeTech and GRU's websites
- 7) For addition benefits, please see items 5-6 under Silver Level

SILVER LEVEL (\$15,000)

- 1) Sponsored Symposium or Presentation(s) during the main program (up to 12 minutes), to be retained on the event website pages and featured in the newsletters of the AdMeTech and GRU with a combined outreach to over 21,000 medical professionals at no additional cost (\$7,000 value)
- 2) Commercial video(s) (up to 3 minutes), shown during main program and retained on the event pages of the AdMeTech and GRU's websites
- 3) 3 complimentary registrations and 3 discounted (50%) registrations
- 4) 3 complimentary tickets to Virtual VIP Strategic Discussions for Speakers and Sponsors (by invitations only).
- 5) Half-page digital ads and other company info (including links) for the event pages of the AdMeTech and GRU's websites
- 6) For addition benefits, please see items 5-6 under Bronze Level

BRONZE LEVEL (\$10,000)

- 1) Sponsored Presentation during the main program (up to 6 minutes), to be retained on the event landing pages of the AdMeTech and GRU websites
- 2) Commercial video(s) (up to total 2 minutes) shown during the main program and retained on the event pages of the AdMeTech and GRU websites
- 3) 2 complimentary registrations and 2 50% discounted registrations
- 4) 2 complimentary tickets to Virtual VIP Strategic Discussions for Speakers and Sponsors (by invitations only).
- 5) Quarter-page digital ads and other company info (including links) for the event pages of the AdMeTech and GRU's websites
- 6) For additional benefits, see items 5-7 under Exhibitor Level

EXHIBITOR LEVEL (\$5,000)

- 1) Sponsored Presentation during the main program (up to 3 minutes), to be retained on the event landing pages of the AdMeTech and GRU websites
- 2) Commercial video(s) (up to 1 minute) shown during the main program and retained on the event pages of the AdMeTech and GRU websites
- 3) 1 complimentary and 1 50% discounted conference registration
- 4) 1 complimentary ticket to Virtual VIP Strategic Discussions for Speakers and Sponsors (by invitations only).
- 5) Company sponsorship is acknowledged in the press release issued by the AdMeTech Foundation and ensuring wide outreach, including the general, business and trade media
- 6) Company logo, mission statement and live link(s) are featured before, during and after the event in all promotional materials, including newsletters and the event pages of the AdMeTech and GRU's websites
- 7) Company is publicly acknowledged in the Conference Opening Remarks

HIGH PROFILE VIDEOS

Highly targeted advertising opportunities when company logo and message will reach the entire conference roster

- One-minute video demonstrated during a scientific session of your choice and retained as the integral part of the Summit 2022 landing pages of the AdMeTech and GRU websites, with their extensive combined outreach (\$2,500)
- Thirty-second video demonstrated during a scientific sessions of your choice and retained as the integral part of the Summit 2022 landing pages of the AdMeTech and GRU websites, with their extensive combined outreach (\$1,250)

SUMMIT REGISTRATIONS

INDUSTRY PARTICIPANTS: \$1,000 for a full 3-day program

ACADEMIC, CLINICAL AND OTHER PARTICIPANTS:

\$650- Early Bird Registration until June 3, 2025
\$750- June 3 to June 30, 2025
\$850- July 1 to July 31, 2025
\$950- August 1 to September 13, 2025
\$1,000- September 15-17, 2025

DISCOUNTED REGISTRATIONS (AT 50%): Available to students, residents, and fellows